Non-Alcoholic Fatty Liver Disease: The Effect of Bile Acids and Farnesoid X Receptor Agonists on Pathophysiology and Treatment
Journal Title: Liver Research – Open Journal - Year 2015, Vol 1, Issue 2
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an emerging epidemic in light of its two predisposing factors, a surge in both obesity and diabetes rates with reports of between 70-80% of obese individuals in Western countries. The disease progression of NAFLD remains elusive but is generally attributed to insulin resistance, lipid metabolism dysfunction, altered immune response to name a few. Potential therapeutic strategies should target one or some of these pathological events in the liver, however currently no specific therapies for NAFLD exist. Thus novel therapeutic approaches to manage the chronic liver disease epidemic are becoming essential. In this review we discuss the evidence supporting the role of bile acid activated Farnesoid X Receptor (FXR) in promoting lipid oxidation, reducing inflammation and fibrosis in the liver. We also examine the potential of FXR agonists, as an attractive class of drugs for the safe and effective treatment of NAFLD.
Authors and Affiliations
Vinood B. Patel
Keywords
Related Articles
- EP ID EP556654
- DOI 10.17140/LROJ-1-106
- Views 140
- Downloads 0
Acute Variceal Bleeding in Patients with Liver Cirrhosis with and without Diabetes
Objectives: To study the effect of diabetes mellitus on presentations, course, and outcome of acute variceal bleeding in cirrhotic patients. Methods: We compared 2 matched groups of patients, a diabetic group and non-dia...
Iron and Copper Toxicity in Rat Liver: A Kinetic and Holistic Overview
Iron (Fe) and copper (Cu) overloads in rats showed a dose and time dependent metal accumulation in liver with its associated toxicity. The increased contents of the transition metals markedly enhanced the endogenous free...
Cardiovascular Disease and NASH
Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) are associated with cardiovascular events and Metabolic Syndrome (MetS). NAFLD is considered to be a hepatic manifestation of MetS and ha...
Pediatric Acute Liver Failure: Current Perspectives
It is well known that acute liver failure (ALF) in children is rare but potentially a life-threatening disorder. Its true incidence in the pediatric population is undetermined but is responsible for 10-15% of all pediatr...
Hepatic Myelopathy: Case Report and Review of the Literature
Background: Hepatic Myelopathy (HM) is a rare complication of chronic liver disease usually associated with extensive portosystemic shunt of blood, which has been created surgically or has occurred spontaneously, causing...